Skip to main content
. 2022 Oct 4;192(2):205–216. doi: 10.1093/aje/kwac170

Figure 2.

Figure 2

Monthly estimated relative risk of Guillain-Barré syndrome (GBS) and Bell’s palsy over time as recombinant zoster vaccine (RZV) was administered in a Vaccine Safety Datalink study cohort, January 2018–December 2019. The large square indicates where the preliminary signal occurred.